Precision Management of Cenobamate in Drug-Resistant Epilepsy: A Case Series

An exploratory case series from 2026 describes five patients selected from a cohort of 125 individuals treated with cenobamate for drug-resistant focal epilepsy. It integrates clinical data, therapeutic drug monitoring, and targeted next-generation sequencing of metabolic genes to examine pharmacogenetic profiles and clinical outcomes. The dataset was authored by Giuseppe d’Orsi and is shared under a CC-BY-4.0 license.

Use Cases

• Investigating relationships between pharmacogenetic profiles and clinical response in epilepsy based on sequencing of UGT and CYP genes.
• Analyzing the role of therapeutic drug monitoring in dose titration strategies based on integrated plasma level data.
• Studying pharmacokinetic contributions to non-response or toxicity based on predicted metabolizer phenotypes.
• Evaluating personalized, sub-target dose titration strategies for minimizing adverse events in polypharmacy settings.

Strengths

• Integrates three data modalities: clinical outcomes, therapeutic drug monitoring, and targeted next-generation sequencing.
• Describes detailed pharmacogenetic analysis of seven key metabolic genes (UGT2B7, UGT2B4, CYP2E1, CYP2B6, CYP2A6, CYP3A4, CYP2C19).
• Includes specific clinical outcomes, such as three patients achieving seizure freedom or ≥50% response at sub-target doses.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 16.8 KB file size suggests a very limited scope, containing primarily a descriptive document rather than a large structured dataset.

Provenance

Source

Giuseppe d’Orsi via figshare

Collection Method

Exploratory case series selected from a clinical cohort.

Freshness

Last updated 2026-06-04 05:40:00; freshness should be verified.